This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lee, J. S. Articles by Hittelman, W. N. Search for Related Content PubMed PubMed Citation Articles by Lee, J. S. Articles by Hittelman, W. N.

Determination of Biomarkers for Intermediate End Points in Chemoprevention Trials¹

Departments of Medical Oncology [J. S. L., S. M. L., W. K. H., S. Y. K., W. N. H.], Tumor Biology [R. L.], and Pathology [J. Y. R.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Renewed interest is being directed toward chemoprevention as a means of reducing cancer mortality. To overcome the inherent problems associated with using cancer development as a study end point, there has recently been a great surge of interest in defining the biomarkers associated with specific stages of the carcinogenic process as intermediate end points. We have detailed the evidence supporting the concept of field cancerization, a concept of general importance that is probably applicable to carcinogenesis and chemoprevention at many organ sites in humans, and presented results of tests of the potentially useful biomarkers proliferating cell nuclear antigen and blood group antigen. Because microassay techniques are more readily applicable to small biopsy samples, further expansion of these studies and exploration of panels of additional biomarkers are expected to generate exciting results in the field of chemoprevention.